Navigation Links
Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
Date:6/13/2008

>wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
3. Angiotech appoints Hank McKinnell to its Board of Directors
4. Angiotech to participate in Bank of America Health Care Conference
5. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
6. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
7. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
8. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
9. Angiotech announces director resignation
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Post Your Comments:
*Name:
*Comment:
*Email: